"With this approval in Italy, we have now received market approval in 17 European countries, and are eagerly awaiting approval also in the UK during 2023. These approvals allow us to offer the first and only registered therapy for inhaled sedation of mechanically ventilated patients in intensive care", says Johannes Doll, President and CEO of Sedana Medical. Sedaconda[®] (isoflurane) has already received pricing and reimbursement approval in Italy. Timing of commercial launch depends on supply availability and the company's distributor for the Italian market, and is expected in the second half of 2023.
Sedana Medical's pharmaceutical Sedaconda (isoflurane), which is administered via the company's unique medical device Sedaconda ACD, is now approved in Austria, Belgium, Croatia, Denmark, Finland, France, Germany, Ireland, Italy, the Netherlands, Norway, Poland, Portugal, Slovenia, Spain, Sweden, and Switzerland.
For additional information, please contact:
Johannes Doll, CEO, +46 (0)76 303 66 66
Johan Spetz, CFO, +46 (0)730 36 37 89
About Sedana Medical
Sedana Medical AB (publ) is a pioneer medtech and pharmaceutical company focused on inhaled sedation to improve the patient's life during and beyond sedation. Through the combined strengths of the medical device Sedaconda ACD and the pharmaceutical Sedaconda (isoflurane), Sedana Medical provides inhaled sedation for mechanically ventilated patients in intensive care.
Sedana Medical has direct sales in Benelux, France, Germany, Great Britain, the Nordics, and Spain. In other parts of Europe as well as in Asia, Australia, Canada, and South- and Central America, the company works with external distributors.
Sedana Medical was founded in 2005, is listed on Nasdaq Stockholm (SEDANA) and headquartered in Stockholm, Sweden.